Massachusetts Eye and Ear Infirmary

Running trials

• Recruiting

  Lactiplantibacillus Plantarum 299v Probiotic Supplementation in Patients With Diabetic Macular Edema

  NCT07383701· Phase 2· Massachusetts Eye and Ear Infirmary· Source

• Recruiting

  Open-label Study of SKY-GJB2 in Pediatric Subjects With GJB2-mediated Hearing Loss

  NCT07627971· Phase 1/2· Skylark Bio Inc.· Source

• Recruiting

  Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)

  NCT07290244· Phase 1· Life Biosciences Inc.· Source

• Recruiting

  Efgartigimod for the Treatment of Acute Optic Neuritis

  NCT06453694· Phase 2· Anastasia Vishnevetsky, MD, MPH· Source

• Recruiting

  A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)

  NCT06942572· Phase 1/2· Splice Bio· Source

• Recruiting

  A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

  NCT06541704· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)

  NCT06646289· Phase 2· MeiraGTx Ocular UK Ltd· Source

• Active, not recruiting

  A Prospective, Observational Study in Adults With Retinitis Pigmentosa (RP)

  NCT06517940· Sumitomo Pharma America, Inc.· Source

• Active, not recruiting

  A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

  NCT06401044· Phase 1/2· Amgen· Source

• Recruiting

  An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

  NCT06435000· Splice Bio· Source

• Recruiting

  Improving Clinical Efficiency by Reducing Scheduled Follow-ups Using Cochlear America's Population Mean Mapping Strategy

  NCT06960616· Massachusetts Eye and Ear Infirmary· Source

• Active, not recruiting

  Oral N-acetylcysteine for Retinitis Pigmentosa

  NCT05537220· Phase 3· Johns Hopkins University· Source

• Recruiting

  Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants

  NCT05589714· Jaeb Center for Health Research· Source

• Active, not recruiting

  Promising ROd-cone DYstrophy Gene therapY

  NCT05748873· Phase 1/2· SparingVision· Source

• Recruiting

  Perceptual Consequences of Cochlear Implant Electrode-neuron Interfaces

  NCT05867173· Massachusetts Eye and Ear Infirmary· Source

• Recruiting

  Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia

  NCT05317390· Massachusetts Eye and Ear Infirmary· Source

• Recruiting

  Brain-Computer Interfaces in Laryngeal Dystonia

  NCT04421365· Kristina Simonyan· Source

• Recruiting

  An fMRI Investigation of the Effects of IV Lidocaine on Tinnitus

  NCT04192773· Early phase 1· D. Bradley Welling, MD, PhD· Source

• Recruiting

  Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD

  NCT04735263· Phase 2· Massachusetts Eye and Ear Infirmary· Source

• Active, not recruiting

  Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

  NCT04794101· Phase 3· MeiraGTx Ocular UK Ltd· Source

• Active, not recruiting

  A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

  NCT03941379· Aura Biosciences· Source

• Active, not recruiting

  Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

  NCT03485209· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

  NCT03052608· Phase 3· Pfizer· Source

• Recruiting

  Imaging Genetics of Laryngeal Dystonia

  NCT03042975· Kristina Simonyan· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Hearing loss4 recruiting
• Dystonia3 recruiting
• Macular degeneration3 recruiting
• Diabetic eye disease1 recruiting
• Essential tremor1 recruiting
• Glaucoma1 recruiting
• Multiple sclerosis1 recruiting
• Neuromyelitis optica (NMOSD)1 recruiting
• Parkinson disease1 recruiting
• Retinitis pigmentosa1 recruiting

Closed trials

• Completed

  Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

  NCT04417530· Phase 2· Aura Biosciences· Source

• Completed

  ctDNA Liquid Biopsy for Early Assessment of Residual Disease in HPV-associated Head and Neck Cancer (Clear-HPVca)

  NCT06730412· Massachusetts Eye and Ear Infirmary· Source

• Withdrawn

  Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma

  NCT04196933· Massachusetts Eye and Ear Infirmary· Source

• Withdrawn

  4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine

  NCT03578354· Phase 2· Massachusetts Eye and Ear Infirmary· Source

• Completed

  Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)

  NCT03349242· MeiraGTx UK II Ltd· Source

• Completed

  Long-term Follow-up Gene Therapy Study for RPGR- XLRP

  NCT04312672· MeiraGTx Ocular UK Ltd· Source

• Completed

  Retinoblastoma Biomarker Study

  NCT00342797· National Cancer Institute (NCI)· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Glaucoma95 works · 1 trial
• Diabetic eye disease49 works · 1 trial
• Macular degeneration46 works · 3 trials
• Hearing loss46 works · 4 trials
• Obstructive sleep apnoea15 works · 0 trials
• Retinitis pigmentosa13 works · 8 trials
• Thyroid cancer9 works · 0 trials
• Dystonia7 works · 3 trials